PDCD1 and neoplasm: In line with our previous results, tumor outgrowth in IgG2b-treated control group of Nr2f6−/− mice was significantly delayed even with this high tumor load and was well comparable to the benefit of blocking the interaction of PD-1 with its ligand PD-L1 in vivo in wild-type mice (Fig. 2a−d).